Page last updated: 2024-11-10

acepreval

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

acepreval: topical steroid used for skin disease therapy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5284612
CHEMBL ID1697848
CHEBI ID135785
SCHEMBL ID375318
MeSH IDM0081287

Synonyms (40)

Synonym
2jb27qjw3d ,
unii-2jb27qjw3d
(11beta)-21-(acetyloxy)-11-hydroxy-3,20-dioxopregna-1,4-dien-17-yl pentanoate
prednisolone valerate acetate
72064-79-0
D03301
prednisolone valerate acetate (jan)
spirazon (tn)
lidomex
11-beta,17-alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-acetate 17-valerate
21-(acetyloxy)-11-beta-hydroxy-17-((1-oxopentyl)oxy)pregna-1,4-diene-3,20-dione
einecs 276-312-8
11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-acetate 17-valerate
11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate 17-valerate
prednisolone 17-valerate 21-acetate
prednisolone valerate acetate [jan]
acepreval
pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-((1-oxopentyl)oxy)-, (11-beta)-
brn 2713941
prednisolone-17-valerate-21-acetate
PDL ,
CHEBI:135785
CHEMBL1697848
prednisolone valeroacetate
[(8s,9s,10r,11s,13s,14s,17r)-17-(2-acetyloxyacetyl)-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl] pentanoate
pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-((1-oxopentyl)oxy)-, (11.beta.)-
prednisolone 21-acetate 17-valerate
prednisolone valeroacetate [who-dd]
11.beta.,17.alpha.,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-acetate 17-valerate
SCHEMBL375318
Q-101384
1,4-pregnadien-11-beta, 17,21-triol-3,20-dione 17-valerate-21-acetate
DTXSID3023506
AKOS027378800
prednival acetate (prednisolone 17-valerate 21-acetate)
(9s,10r,11s,13s,14s,17r)-17-(2-acetoxyacetyl)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl pentanoate
(8s,9s,10r,11s,13s,14s,17r)-17-(2-acetoxyacetyl)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl pentanoate
NCGC00532510-01
(11beta)-21-(acetyloxy)-11-hydroxy-17-[(1-oxopentyl)oxy]pregna-1,4-diene-3,20-dione
Q27254822

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" From the above evidence, it was concluded that HBP ointment was less toxic than the other topical corticosteroids."( Comparative toxicity study of hydrocortisone 17-butyrate 21-propionate (HBP) ointment and other topical corticosteroids in rats.
Kimura, M; Nakane, S; Otomo, S; Tarumoto, Y, 1986
)
0.27

Bioavailability

ExcerptReferenceRelevance
" In addition to their drug targeting application and their ability to improve bioavailability of drugs, nanoparticles can be designed to allow their detection with a variety of imaging methodologies."( Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer.
Calcagno, C; Dijk, WJ; Fayad, ZA; Gianella, A; Griffioen, AW; Jarzyna, PA; Kann, B; Mani, V; Mulder, WJ; Ramachandran, S; Storm, G; Tang, J; Thijssen, VL, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (57.14)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]